Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Transcriptomic signatures associated with deep molecular response to ropeginterferon alfa-2b in polycythemia vera

View Full Paper
Ask AI
Bookmark
Share

Authors

SYSung-Soo YoonDYDeok‐Hwan YangSSSang Kyun Sohn

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows immune activation and distinct molecular responses in polycythemia vera patients receiving ropeginterferon alfa-2b.

Key Points

  • The study aimed to evaluate the deep molecular response to ropeginterferon alfa-2b in polycythemia vera patients.
  • Conducted a phase 2, multicenter, prospective clinical trial in Korea
  • Evaluated molecular responses at week 132 using ELN criteria and absolute allele burden thresholds
  • Performed RNA sequencing to analyze transcriptomic features associated with molecular response
  • Assessed JAK2 V617F allele burden using quantitative PCR
  • 88.9% of patients achieved molecular response based on ELN criteria
  • 41.3% achieved deep molecular response with allele burden <2%
  • Transcriptomic analysis identified 650 differentially expressed genes between DMR and non-DMR groups
  • GO analysis revealed significant upregulation of immune-related processes in DMR patients
  • KEGG pathway analysis showed enrichment in immune and hematopoietic pathways

Cite This Study

Yoon et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d788https://doi.org/10.1182/blood-2025-2040
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical significance of earlier CHR achievement and long-term CHR maintenance in polycythemia vera patients treated with ropeginterferon alfa-2b2025
  2. 2Complete Hematological Response Coupled with Molecular Response in Polycythemia Vera Treatment with Ropeginterferon Alfa-2b2026
  3. 3Long-term efficacy and safety of ropeginterferon alfa-2b under its hidat regimen for the treatment of polycythemia vera2025
  4. 4Hematologic and molecular response to ropeginterferon alfa-2b in patients with polycythemia vera: a systematic review and meta-analysis.2026
  5. 5Ropeginterferon dose-escalation strategies in polycythemia vera: a systematic review and meta-analysis2026